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Supplementary Information on Chemical Synthesis
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Experimental Part:
General reagents and materials
12-methyl tridecanol was from Endeavour Speciality Chemicals, all other starting compounds and 
solvents were purchased from Sigma-Aldrich/Fluka or Acros and were used without further 
purification. Column chromatographic separations were carried out using 230-400 mesh silica gel. TLC 
plates were developed with potassium permanganate mixture (1 g of KMnO4, 2 g of Na2CO3, 100 mL 
of H2O). 1H, and 13C NMR spectra were recorded (as indicated) on either a Bruker 300 MHz or 400 
MHz spectrometer and are reported as chemical shifts (δ) in ppm relative to TMS (δ = 0). Spin 
multiplicities are reported as a singlet (s) or triplet (t) with coupling constants (J) given in Hz, or 
multiplet (m). ESI-MS for the characterization of compounds was performed on an ESI API 150EX 
and are reported as mass-per-charge ratio. IR spectra were recorded on a Perkin Elmer Spectrum One 
FT-IR spectrometer (ATR, Golden Gate). Optical rotation was measured on a Jasco P-1030 polarimeter. 
All reactions were performed under an Ar or N2 atmosphere.
(S)-N-methoxy-N-methyl-1-((R)-1-phenylethyl)aziridine-2-carboxamide (2)
A literature protocol was followed.1
Method A : To (2S)-2-isopropyl-4-methoxycyclohexyl 1-((R)-1-phenylethyl)aziridine-2-carboxylate 1 
(1.00 g, 2.89 mmol, 1 equiv.) and Weinreb's amine or N,O-dimethylhydroxylamine.HCl (450 mg, 7.4 
mmol, 2.5 equiv.) in 10 mL THF was slowly added isopropyl magnesium chloride (4.60 mL, 9.2 
mmol, 3.2 equiv., 2.0 M in THF) at 0 °C. The resulting mixture was warmed to rt and after 30 min, it 
was partitioned between CH2Cl2 and H2O. The water phase was washed with CH2Cl2 (3 × 20 mL). The 
combined organic solvents were dried over MgSO4 and the solvent was evaporated under reduced 
pressure. The crude product was purified on a silica gel column (EtOAc/Pentane gradient 1:1 to 1:0) in 
order to give Weinreb’s amide or N-(R)-(+)-α-methylbenzyl-2-(S)-aziridine N-Methoxy-N-
methylcarboxamide 2 as a white powder (298 mg, 44 %).
Method  B : To the solid of N,O-dimethylhydroxylamine⋅HCl (880 mg, 9.11 mmol, 3 equiv.) in 10 mL 
of CH2Cl2 was carefully added trimethylaluminium (4.55 mL, 9.11 mmol, 3 equiv., 2.00M) under 
nitrogen at -10 °C. The solution was stirred for 30 min at rt and then a solution of (2S)-2-isopropyl-4-
methoxycyclohexyl 1-(R-1-phenylethyl)aziridine-2-carboxylate 1 (1.00 g, 3.04 mmol) in 5.0 mL 
CH2Cl2 was added dropwise at -10 °C. The mixture was stirred for 2 h at rt. Then the reaction was 
quenched carefully with water and the organic layer was separated. After extraction with CH2Cl2 (3 × 
20 mL), the combined organic layers were dried, filtered, and concentrated under vacuum. Purification 
by silica gel flash chromatography (EtOAc/cyclohexane, 75:15 to 50:50 to 100:0) yielded pure N-(R)-
(+)-α-methylbenzyl-2-(S)-aziridine N-Methoxy-N-methylcarboxamide 2 as an oil (321 mg, 45%).
[α]22D = + 13.1 (c 1.00, CHCl3).2
Rf=0.10 (EtOAc/Pentane 1:0).
1H NMR (300 MHz, CDCl3) : δ = 7.44 – 7.08 (m, 5H) , 3.11 (d, J = 8.3 Hz, 6H), 2.55 (q, J = 6.4 Hz, 
2H), 2.40 (d, J = 3.0 Hz, 1H), 1.74 (d, J = 6.4 Hz, 1H), 1.46 (d, J = 6.5 Hz, 3H).
1 J-W. Kim, Y-W. Kim, Y. Inagaki, Y-A. Hwang, S. Mitsutake, Y-W. Ryu, W. K. Lee, H-J. Ha, C-S. Park, Y.Igarashi, 
Bioorganic & Medicinal Chemistry, 2005, 13, 3475-3485.
2 This value has been confirmed by personal communication with Ha et al. The reported value in J. Org. Chem. 2003, 68, 7675-
7680 stands corrected.
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1-bromo-12-methyltridecane (4)
Method A : 12-methyl-1-tridecanol 3 (1.00 g, 4.66 mmol) was dissolved in CH3CN and 
bromotrimethylsilane (1.79 g, 11.7 mmol, 2.5 equiv.) was added. The solution was heated to 90 °C for 
5 h. Then 2 mL H2O were added. The solvents were removed under reduced pressure and the crude 
material was purified on a silica gel column (hexanes) in order to give 1-bromo-12-methyltridecane as 
a clear oil (380 mg, 29 %).
Method B : 12-methyl-1-tridecanol 3 (2.00 g, 9.3 mmol) was dissolved in CH2Cl2 (25 mL) and PPh3 
(4.40 g, 16.6 mmol, 1.2 equiv.), and pyridine (1.3 mL, 16.6 mmol, 1.2 equiv.) were added. The flask 
was cooled down to 0 °C after that bromine Br2 was added dropwise (0.56 mL, 16.6 mmol, 1.2 equiv.). 
The solution became orange and the reaction was stirred for 3 h at rt. The solvent was removed under 
reduced pressure and the orange crude material was filtered on a silica gel column using CH2Cl2 to 
afford to 1-bromo-12-methyltridecane 4 as yellow oil (3.42 g, 88 %).
Rf = 0.75 (Hexanes).
1H NMR3 (400 MHz, CDCl3) : δ = 3.45 (t, J = 6.9 Hz, 2H), 1.98 – 1.79 (m, 2H), 1.66 – 1.51 (m, 1H),  
1.47 (dd, J = 14.3, 7.0 Hz, 2H), 1.32 (d, J = 7.3 Hz, 14H), 1.20 (dd, J = 13.3, 6.5 Hz, 2H), 0.92 (d, J = 
6.6 Hz, 6H).
3 J.Y. Mun, A. Onorato, F. C. Nichols, M. D. Morton, A. I. Saleh, M. Welzel, M. B. Smith. Organic & Biomolecular Chemistry, 
2007, 5, 3826-3833.
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13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-one (6)
1-bromo-12-methyltridecane 4 (413 mg, 1.7 mmol, 1.5 equiv.) was dissolved in 2 mL THF. Mg 
turnings (40.3 mg, 1.7 mmol, 1.5 equiv.) were added together with a drop of I2. The reaction was 
heated in order to initiate the Grignard reaction. The mixture of 5 was slowly added to (S)-N-methoxy-
N-methyl-1-((R)-1-phenylethyl)aziridine-2-carboxamide 2 (259 mg, 1.1 mmol) in 5 mL THF at -78 °C. 
The reaction was stirred for 30 min and then the cold-bath was removed. After reaching rt, the mixture 
was quenched with 5 mL H2O and extracted with CH2Cl2 (3 × 10 mL). The organic phase was dried 
over MgSO4, filtered, and the solvents were removed under reduced pressure. The crude material was 
purified on a silica gel column (EtOAc/Pentane 1:4) and the pure compound 6 was isolated as a clear 
oil (199 mg, 0.54 mmol, 48 %). 
 [α]24D = - 53.9 (c 1.00, CHCl3).
Rf = 0.40 (EtOAc:Pentane 1:9).
HRMS-ESI (m/z) : [M+H]+ calcd for C25H42NO: 372.326; found 372.3259.
IR (Golden Gate) : 2925 (s), 2853 (m), 1702 (m), 1451 (w).
1H NMR (300 MHz, CDCl3) : δ = 7.28 – 7.15 (m, 5H), 2.48 (q, J = 6.6 Hz, 1H), 2.37 – 2.25 (m, 1H), 
2.23 – 2.11 (m, 2H), 2.06 (dd, J = 6.7, 3.1 Hz, 1H), 1.73 (d, J = 6.8 Hz, 1H), 1.53 – 1.43 (m, 1H), 1.42 
– 1.31 (m, 5H), 1.26 – 1.02 (m, 18H), 0.81 (d, J = 6.6 Hz, 6H).
4
13C NMR (101 MHz, CDCl3) : δ = 208.73, 143.96, 128.48, 127.30, 126.59, 70.05, 44.02, 39.10, 38.65, 
35.47, 29.99, 29.76, 29.71, 29.66, 29.50, 29.41, 29.19, 28.01, 27.47, 23.47, 22.72.
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(R)-13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-ol (7)
Method A : To 13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-one 6 (150 mg, 
404 μmol) in 2 mL dry MeOH at - 78 °C, was added ZnCl2 (81.0 mg, 594 μmol, 1.47 equiv.). After 
30 min. NaBH4 (29.5 mg, 780 μmol, 1.9 equiv.) was added and the mixture was stirred for additional 
30 min. Then, 5 mL H2O was added at -78 °C and the reaction was left to reach rt. The water phase 
was extracted with CH2Cl2 (3 × 10 mL). The organic phase was dried over MgSO4, filtered, and 
evaporated under reduced pressure. The crude material was purified on a silica gel column 
(EtOAc/Hexanes 3:7) and the pure compound 7 was isolated (95.0 mg, 254 μmol, 63 %).
Method B : To 13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-one 6 (55 mg, 148 
μmol) in 2 mL dry MeOH –t - 78 °C was added ZnCl2 (29.7 mg, 217.8 μmol). After 30 min. NaBH4 
(10.8 mg, 285.5 μmol, 1.47 equiv.) was added and the mixture was stirred for additional 30 min. Then, 
H2O (1 mL) was added at -78 °C and the reaction was left to reach rt. The water phase was extracted 3 
times with CH2Cl2. The organic solvent was dried over MgSO4, filtered, and evaporated under reduced 
pressure. The crude material 7 (44 mg, crude yield : 80 %) was directly used in the followed step.
[α]24D = + 7.0 (c 0.50, CHCl3).
Rf = 0.10 (EtOAc/Hexanes 3:7).
HRMS-ESI (m/z): [M+H]+ calcd for C25H44NO: 374.3417; found 374.3413.
IR (Golden Gate): 2926 (s), 2851 (m), 1703 (m), 1371 (m), 1287 (m).
1H NMR (300 MHz, CDCl3) : δ = 7.30 – 7.23 (m, 4H), 7.22 – 7.13 (m, 1H), 3.52 – 3.41 (m, 1H), 2.53 
(q, J = 6.5 Hz, 1H), 1.92 (d, J = 3.4 Hz, 1H), 1.55 – 1.48 (m, 1H), 1.47 – 1.39 (m, 1H), 1.38 – 1.30 (m, 
4H), 1.26 – 1.01 (m, 22H), 0.81 (d, J = 6.6 Hz, 6H).
13C NMR (101 MHz, CDCl3) : δ = 144.35, 128.47, 127.20, 126.64, 99.99, 69.36, 68.34, 42.17, 39.10, 
34.71, 29.99, 29.77, 29.72, 29.63, 29.57, 28.01, 27.47, 25.27, 23.15, 22.72.
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(2S,3R)-15-methyl-2-(((R)-1-phenylethyl)amino)hexadecane-1,3-diol (8)
Method A : To (R)-13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-ol 7 (82.2 mg, 
220 μmol) in 2 mL of CH2Cl2 was added acetic acid (66.0 μL, 1.10 mmol, 5 equiv.) and the reaction 
was stirred for 18 h. Then 1 mL of NaHCO3 (sat.) was added and the solution was extracted with 
CH2Cl2 (4 × 10 mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated 
under reduced pressure. The crude material was purified over a short silica gel column (EtOAc) to give 
pure compound 8 (28.3 mg, 72.2 μmol, 33 %).
Method B : To (R)-13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)tetradecan-1-ol 7 (25 mg, 66 
μmol) in 0.8 mL of CH2Cl2 was added acetic acid (20.0 μL, 0.33 mmol, 5 equiv.) and the reaction was 
stirred for 2 days. Then 16 μL of acetic acid were added and the mixture was stirred for 2 h. Then 5 mL 
of NaHCO3 (sat.) was added and the solution was extracted with CH2Cl2 (3 × 10 mL) and brine (3 × 10 
mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated under reduced 
pressure. The crude product (clear oil, colorless) was purified over a short silica gel column (EtOAc), 
dissolved in 5 mL of CH2Cl2 and 20 μL of acetic acid were added. After 18 h, the reaction was 
quenched with 1 mL of NaHCO3 and the solution was extracted with CH2Cl2 (3 × 10 mL). The organic 
phase was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. Then, 
the product was dissolved in 0.5 mL of EtOH and 4.2 mg (75 mmol) of KOH were added. After stirring 
for 1.5 h the solvent was evaporated under reduced pressure. After the addition of H2O, the solution 
was extracted with CH2Cl2 (3 × 10 mL), the organic phase was dried over MgSO4, filtered and the 
solvent was evaporated under reduced pressure. A short silica gel column (EtOAc) afforded compound 
8 (19 mg, 50 μmol) in 74 % yield. 
[α]24D = + 21.5 (c 1.00, CHCl3).
Rf = 0.19 (EtOAc).
HRMS-ESI (m/z): [M+H]+ calcd for C25H46NO2: 392.3523; found 392.3526.
IR (Golden Gate): 3349 (br), 2923 (s), 2852 (m), 1466 (m), 1366 (s), 1065 (m).
1H NMR (400 MHz, CDCl3) : δ = 7.36 (dd, J = 10.2, 2.8 Hz, 4H), 7.33 – 7.19 (m, 1H), 3.96 (q, J = 6.5 
Hz, 1H), 3.76 (d, J = 4.1 Hz, 2H), 3.63 – 3.52 (m, 1H), 2.49 (dd, J = 8.0, 4.0 Hz, 2H), 1.62 – 1.52 (m, 
1H), 1.48 – 1.40 (m, 6H), 1.35 – 1.18 (m, 20H), 0.91 (d, J = 6.6 Hz, 6H).
13C NMR (101 MHz, CDCl3) : δ = 145.64, 128.59, 127.18, 126.62, 73.59, 60.28, 58.92, 55.94, 39.10, 
33.80, 29.99, 29.77, 29.72, 29.69, 29.63, 29.59, 29.56, 28.01, 27.47, 26.12, 24.60, 22.71.
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(2S,3R)-2-amino-15-methylhexadecane-1,3-diol (9)
Method A : To (2S,3R)-15-methyl-2-(((R)-1-phenylethyl)amino)hexadecane-1,3-diol 8 (28.3 mg, 72 
μmol) in 5 mL MeOH was added Pd(OH)2/C (5 mg) and the mixture was stirred under 1 atm. of H2 for 
48 h. Then the mixture was filtered and the solvents were evaporated under reduced pressure. The 
crude material was purified on a silica gel column (CH2Cl2/MeOH/NH4OH 0.875:0.11:0.015) to give 
compound 9 (4.20 mg, 14.6 μmol) in 20 % yield.
Method B : To (2S,3R)-15-methyl-2-(((R)-1-phenylethyl)amino)hexadecane-1,3-diol 8 (27 mg, 48 
μmol) in 5 mL MeOH was added Pd/C (10 mg) and the mixture was stirred under 1 atm. of H2 
overnight. Then the mixture was filtered over celite and the solvent was evaporated under reduced 
pressure to afford to the compound 9 (8 mg, 27.8 μmol ) in 58 % yield.
[α]22D = - 4.4 (c 0.33, CHCl3).
Rf  = 0.27 (CH2Cl2/MeOH/NH4OH 0.875:0.11:0.015).
HRMS-ESI (m/z) : [M+H]+ calcd for C17H38NO2: 288.2897; found 288.2892.
IR (Golden Gate) : 3339 (br), 2922 (s), 2852 (m), 1467 (m), 1384 (w), 1366 (w), 1215 (w), 1051 (w).
1H NMR (500 MHz, CDCl3) : δ = 3.73 – 3.67 (m, 2H), 3.66 – 3.58 (m, 1H), 2.88 (br, OH, OH, NH2, 
4H), 2.81 – 2.80 (m, 1H), 1.55 – 1.45 (m, 4H), 1.30 – 1.26 (m, 17H), 1.15 (dt, J = 7.3, 6.5 Hz, 2H), 
0.86 (d, J = 6.6 Hz, 6H).
13C NMR (126 MHz, CDCl3) : δ = 74.48, 63.34, 55.77, 39.08, 33.84, 29.97, 29.76, 29.74, 29.72, 29.71, 
29.68, 27.98, 27.44, 26.14, 22.67.
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(2S,3R)-2-amino-15-methylhexadecan-3-ol (10)
Method A : To (R)-13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl) tetradecan-1-ol 7, (25 mg, 150 
μmol) in 1.8 mL MeOH was added Pd/C (1.3 mg) and the mixture was stirred under 1 atm. of H2 for 
48 h. Then the mixture was filtered and the solvent was evaporated under reduced pressure. The crude 
material was purified on a silica gel column (CH2Cl2/MeOH/NH4OH 0.875:0.11:0.015) to give 
compound 9 (3 mg, 11 μmol, 8 %).
Method B : To (R)-13-methyl-1-((S)-1-((R)-1-phenylethyl)aziridin-2-yl) tetradecan-1-ol 7 (65.9 mg, 
176 μmol) in 5 mL MeOH was added Pd(OH)2/C (7 mg,) and the mixture was stirred under 1 atm. of 
H2 for 48 h. Then the mixture was filtered and the solvents were evaporated under reduced pressure. 
The crude material was purified on a silica gel column (CH2Cl2/MeOH/NH4OH 0.875:0.11:0.015) to 
give compound 10 (20.2 mg, 74.4 μmol, 42 %).
[α]24D = + 8.6 (c 1.00, CHCl3).
Rf = 0.15 (CH2Cl2/MeOH/NH4OH 0.875:0.11:0.015).
HRMS-ESI (m/z): [M+H]+ calcd for C17H38NO: 272.2947; found 272.2950.
IR (Golden Gate): 2915 (s), 2850 (s), 1587 (m), 1468 (m), 1366 (m), 1093 (m).
1H NMR (400 MHz, CDCl3) δ 3.49 (dt, J = 4.2, 3.8 Hz, 1H), 3.01 (dq, J = 6.2, 3.3, 3.2 Hz, 1H), 2.25 
(br, OH/NH2, 3H), 1.55 – 1.47 (m, 2H), 1.44 – 1.35 (m, 2H), 1.30 – 1.26 (m, 17H), 1.17 – 1.13 (m, 
2H), 1.04 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.6 Hz, 6H).
12
13C NMR (125.76 MHz, CDCl3) δ 74.33, 50.49, 39.07, 32.50, 29.96, 29.78, 29.74, 29.67, 29.69, 29.64, 
29.63, 27, 98, 27.43, 26.21, 22.67, 16.37.
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Supplementary Figures:
Supplementary Figure 1.
Labelling of C. elegans sphingoid bases using amino acids. (a) C17 sphingoid bases detected in 
animals fed with bacterial diets containing heavy amino acids leucine, isoleucine, valine or lysine, the 
light and the 13C-containing +4 and +5 isotopic peaks are shown; (b) relative amounts of +5 isotopic 
peak with 13C label incorporation compared to light C17 sphingoid base without isotopic peak 
correction; (c) scheme of label incorporation from heavy isotope labelled amino acids via branched 
chain fatty acids into sphingoid bases.
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Supplementary Figure 2.
Calculation of width of GFP positive intestinal lumen and width of F-actin signal visualized by SiR-
actin. (a-b) representative line profile of fluorescent signals from OP50 GFP in the intestinal lumen 
(cyan line, a) and SiR-actin (magenta line, b) and their Gaussian fits (dashed lines) recorded 
perpendicular to the intestinal lumen in animals treated with ethanol vehicle; (c)-(e) average Gaussian 
fits of GFP signals (cyan) and SiR-actin (magenta) for animals treated with solvent control EtOH (c), 
C17 iso-branched sphinganine, id17:0 (d) and 1-deoxy C17 iso-branched sphinganine, im17:0 (e); (f) 
width of the intestinal lumen as given by the full width at half maximum of a single Gaussian fit of the 
GFP signal; (g) width of the apical F-actin signal as calculated by the width of two Gaussian fits of the 
SiR-actin signal, statistical significance determined by Welch’s t-test * p<0.05, *** p<0.005.
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Supplementary Figure 3.
Saturated image of Figure 5 to better visualize growth of lcb1Δ strain on racemic C16 DL-sphinganine 
(DL-d16:0).
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